Skip to content
10-Q

Quarterly Report

Tempest Therapeutics, Inc. TPST

0001193125-26-224289

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 14.81M sh
Shares Diluted Q1 2026 · Mar 31, 2026 10.93M sh
Shares Diluted Q1 2026 · Mar 31, 2025 3.44M sh
Capex Q1 2026 · Mar 31, 2026 $0
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$7.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$8.04M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $1.81M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $7.71M
Stockholders Equity Q1 2026 · Mar 31, 2026 $822K
Stockholders Equity Q1 2026 · Dec 31, 2025 $6.67M
Stockholders Equity Q1 2026 · Mar 31, 2025 $11.13M
Stockholders Equity Q1 2026 · Dec 31, 2024 $19.13M
Current Liabilities Q1 2026 · Mar 31, 2026 $3.31M
Current Liabilities Q1 2026 · Dec 31, 2025 $3.31M
Total Liabilities Q1 2026 · Mar 31, 2026 $9.93M
Total Liabilities Q1 2026 · Dec 31, 2025 $10.26M
Current Assets Q1 2026 · Mar 31, 2026 $2.45M
Current Assets Q1 2026 · Dec 31, 2025 $8.27M
Total Assets Q1 2026 · Mar 31, 2026 $10.75M
Total Assets Q1 2026 · Dec 31, 2025 $16.93M
Eps Diluted Q1 2026 · Mar 31, 2026 −$2.53
Eps Diluted Q1 2026 · Mar 31, 2025 −$3.16
Eps Basic Q1 2026 · Mar 31, 2026 −$2.53
Eps Basic Q1 2026 · Mar 31, 2025 −$3.16
Net Income Q1 2026 · Mar 31, 2026 −$27.7M
Net Income Q1 2026 · Mar 31, 2025 −$10.86M
Operating Income Q1 2026 · Mar 31, 2026 −$27.72M
Operating Income Q1 2026 · Mar 31, 2025 −$10.94M